Enhanced Computed Tomography or Magnetic Resonance Imaging: A Choice between Contrast Medium-Induced Nephropathy and Nephrogenic Systemic Fibrosis?

References

• Boyd A. S., Zic J. A., Abraham J. L. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007; 56: 27–30
   PubMed Web of Science ®Google Scholar
• Broome D. R., Girguis M., Baron P., Cottrel A., Kjellin I., Kirk G. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Am J Roentgenol 2007; 188: 586–92
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention (CDC). Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents – St. Louis, Missouri, 2002–2006. MMWR Morb Mortal Wkly Rep 2007; 56: 137–41
   PubMedGoogle Scholar
• Deo A., Fogel M., Cowper S. E. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. J Am Soc Nephrol 2007, Epub
   Web of Science ®Google Scholar
• Dharnidharka V. R., Wesson S. K., Fennell R. S. Gadolinium and nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol 2006, Epub
   PubMed Web of Science ®Google Scholar
• EMEA Decision, February 7, 2007. 2007. Available at URL: www.esur.org. Accessed: March 14, 2007.
   Google Scholar
• Evenepoel P., Zeegers M., Segaert S., Claes K., Kuypers D., Maes B., et al. Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrol Dial Transplant 2004; 49: 469–73
   Google Scholar
• Grobner T. Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 2006; 21: 1104–8
   PubMed Web of Science ®Google Scholar
• High W., Ayers R. A., Chandler J., Zito G., Cowper S. E. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56: 27–30
   PubMed Web of Science ®Google Scholar
• Idée J. -M., Port M., Raynal I., Schaefer, Le Greneur S., Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006; 20: 563–76
   PubMed Web of Science ®Google Scholar
• Khurana A., Runge V. M., Narayanan M., Greene J. F., Nickel A. E. Nephrogenic systemic fibrosis. A review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 2007; 42: 139–45
   PubMed Web of Science ®Google Scholar
• Maloo M., Abt P., Kashyap R., Younan D., Zand M., Orloff M., et al. Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transpl 2006; 6: 2212–7
   PubMed Web of Science ®Google Scholar
• Marckmann P., Skov L., Rossen K., Dupont A., Damholt M. B., Heaf J. G., et al. Nephrogenic systemic fibrosis: suspected etiological role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 2359–62
   PubMed Web of Science ®Google Scholar
• Morcos S. K. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast molecule an important factor in the pathogenesis of this condition?. Br J Radiol 2007, Epub
   PubMed Web of Science ®Google Scholar
• Roditi G., Collidge T. A., Thomson P. C., Mark P. B., Traynor J. P., Jardine A., et al. A retrospective case-control study of gadolinium-enhanced magnetic resonance imaging and nephrogenic systemic fibrosis in patients with renal failure., ECR'07; B-100
   Google Scholar
• Sadowski E., Bennett L. K., Chan M. R., Wentland A. L., Garrett A. L., Garrett R. W., et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243: 148–57
   PubMed Web of Science ®Google Scholar
• Thomsen H. S. Current evidence on prevention and management of contrast induced nephropathy. Eur Radiol 2007, in press
   Google Scholar
• Thomsen H. S. Extracellular gadolinium agents: latest evidence in tolerance and complications., ECR'07; A-384
   Google Scholar
• Thomsen H. S. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 2006; 16: 2619–21
   PubMed Web of Science ®Google Scholar
• Thomsen H. S., Almén T., Morcos S. K., Members of Contrast Media Safety Committee of European Society of Urogenital Radiology. Gadolinium-containing contrast media for radiographic examinations: a position paper., Eur Radiol. 12. 2600–5
   Google Scholar
• Thomsen H. S., Morcos S. K., Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). In which patients should serum-creatinine be measured before contrast medium administration?, Eur Radiol. 15. 749–54
   Google Scholar
• Yerram P., Saab G., Karuparthi P. R., Hayden M., Khanna R. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure – role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. J Am Soc Nephrol 2007, Epub
   Web of Science ®Google Scholar